CD276 and cancer: CD276 is a promising cancer treatment target, and Feng et al. [158] referenced the literature to develop a fully human CD276 monoclonal antibody–drug conjugate that significantly improved the therapeutic index and provides an advanced ADC development platform for effective and selective targeting of various types of solid tumors.